Search

The chemistry and biology of novel TXA2(TP)-receptor agonists based on the prostanoid skeleton is described and structure-activity-relationships are discussed. One compound,(5Z,13E), (9R,15R)-9-fluoro-15-hydroxy-16-phenoxy-17,18,19,20-tetranor- 5,13-prostadienoic acid (33), was identified which is 10 times more potent than the standard TP-receptor against U 46619.

Several prostaglandin D (PGD) analogues have been synthesized, incorporating the following variations: (a) varying degrees of side-chain unsaturation, (b) C-9 hydroxy removed or in the unnatural 9 beta configuration, (c) metabolically stabilized analogues (e.g., 15-methyl, 16,16-dimethyl, 17-phenyl, etc.), and (d) delta 12 isomers resulting from decomposition of PGD2. With regard to their ability to inhibit adenosine diphosphate (ADP) induced human platelet aggregation: (a) PGD3 greater than or equal to PGD2 greater than PGD1 greater than 13,14-dihydro-PGD1, (b) the 9 beta- and 9-deoxy-PGD2 analogues are more potent than PGD2, (c) metabolically stabilized analogues with bulky substituents at or near C-15 have substantially reduced antiaggregatory activity relative to PGD2 and (d) the delta 12 isomers of PGD2 are much less active than PGD2.

Prostaglandins (PG) are endogenous compounds that have been extensively studied by various techniques. In this paper, the syntheses of methyl esters of PGD2 and PGE2, labelled with 11C for PET investigations, are reported. The prostaglandin was esterified via its carboxylate anion, with [11C]methyl iodide as alkylating reagent, in a dimethyl sulphoxide-dimethylformamide mixture. To minimize the base-catalysed degradations, the carboxylate anion was generated in situ by use of tetramethylpiperidine. The radiochemical yield, including purification, was 70%, with a total synthesis time of 20-25 min counted from the end of the [11C]methyl iodide synthesis.